Tina Susan  Nova net worth and biography

Tina Nova Biography and Net Worth

Dr. Tina Susan Nova Ph.D. serves as Independent Chairman of the Board of the Company. She has served as a member of our Board of Directors since September 2004 and as Chair of the Board since June 2016. Dr. Nova previously served as the Board’s lead independent director from June 2015 to June 2016. Dr. Nova has served as President and Chief Executive Officer of Decipher Biosciences, Inc. (formerly GenomeDx, Inc.), a molecular diagnostics company focused in prostate cancer, since September 2018. Dr. Nova served as President and Chief Executive of Molecular Stethoscope, Inc. from September 2015 to August 2018. Dr. Nova served as Senior Vice President and General Manager of Illumina Inc.’s oncology business unit from July 2014 to August 2015. Dr. Nova was a co-founder of Genoptix, Inc., a medical laboratory diagnostics company, and served as its President from 2000 to April 2014. Dr. Nova also served as the Chief Executive Officer of Genoptix and as a member of its board of directors from 2000 until Novartis AG acquired Genoptix in March 2011. Dr. Nova was a co-founder of Nanogen, Inc., a provider of molecular diagnostic tests, and she served as its Chief Operating Officer and President from 1994 to 2000. Dr. Nova served as Chief Operating Officer of Selective Genetics, a biotechnology company, from 1992 to 1994, and in various director-level positions with Ligand Pharmaceuticals Incorporated, a drug discovery and development company, from 1988 to 1992, most recently as Executive Director of New Leads Discovery. Dr. Nova has also held various research and management positions with Hybritech, Inc., a former subsidiary of Eli Lilly & Company, a pharmaceutical company. Dr. Nova serves as a member of the board of directors of Veracyte, Inc., a diagnostics company, and OpGen, Inc., an infection prevention and treatment company.

What is Tina Susan Nova's net worth?

The estimated net worth of Tina Susan Nova is at least $1.78 million as of August 26th, 2020. Dr. Nova owns 17,776 shares of Arena Pharmaceuticals stock worth more than $1,777,422 as of April 19th. This net worth estimate does not reflect any other assets that Dr. Nova may own. Learn More about Tina Susan Nova's net worth.

How do I contact Tina Susan Nova?

The corporate mailing address for Dr. Nova and other Arena Pharmaceuticals executives is 6154 Nancy Ridge Drive, San Diego CA, 92121. Arena Pharmaceuticals can also be reached via phone at (858) 453-7200 and via email at [email protected]. Learn More on Tina Susan Nova's contact information.

Has Tina Susan Nova been buying or selling shares of Arena Pharmaceuticals?

Tina Susan Nova has not been actively trading shares of Arena Pharmaceuticals within the last three months. Most recently, Tina Susan Nova sold 17,300 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $67.94, for a transaction totalling $1,175,362.00. Following the completion of the sale, the director now directly owns 17,776 shares of the company's stock, valued at $1,207,701.44. Learn More on Tina Susan Nova's trading history.

Who are Arena Pharmaceuticals' active insiders?

Arena Pharmaceuticals' insider roster includes Vincent Aurentz (VP), Christopher Cabell (CMO), Jayson Dallas (Director), Robert Lisicki (EVP), Amit Munshi (CEO), Tina Nova (Director), and Manmeet Soni (Director). Learn More on Arena Pharmaceuticals' active insiders.

Tina Susan Nova Insider Trading History at Arena Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/26/2020Sell17,300$67.94$1,175,362.0017,776View SEC Filing Icon  
3/7/2019Sell1,200$45.99$55,188.0012,676View SEC Filing Icon  
4/14/2014Sell35,000$6.22$217,700.0018,728View SEC Filing Icon  
See Full Table

Tina Susan Nova Buying and Selling Activity at Arena Pharmaceuticals

This chart shows Tina Susan Nova's buying and selling at Arena Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arena Pharmaceuticals Company Overview

Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $99.99
Low: $99.99
High: $99.99

50 Day Range

MA: $97.65
Low: $93.13
High: $99.99

2 Week Range

Now: $99.99
Low: $45.50
High: $100.00

Volume

107 shs

Average Volume

1,561,326 shs

Market Capitalization

$6.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55